Analyzing...
Loading company...
Nothing flagged for monitoring
“Services business in Healthcare — Hospitals & Diagnostics.”
₹687 Cr service revenue.
Employee costs at 18.4% of revenue — primary cost driver.
“I have consistently been guiding that our long term growth rate will be mid teens.”
“consolidated level, we delivered revenue growth of 18% year on year, primarily driven by our Pathology business, which grew 20% year on year.”
“growth rate point of view is definitely achievable, but it will come at a cost.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 25.8%▲ | 7.9% |
| ROCE | 35.4%▲ | 11.3% |
| Net Margin | 17.0%▲ | 9.3% |
| EBITDA Margin | 31.6%▲ | 21.9% |
| Debt To Equity | 0.00x▼ | 0.16x |
| Rev Growth 3yr | 4.3%▼ | 12.4% |
| EPS Growth 3yr | -19.6%▼ | 11.8% |
| Employee Cost Ratio | 18.40x | - |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹792 Cr +15.3% | ₹687 Cr +20.2% | ₹572 Cr +8.6% | ₹527 Cr -10.6% | ₹589 Cr +19.1% | ₹495 Cr +14.2% | ₹433 Cr +7.5% | ₹403 Cr |
| Other Income | ₹17 Cr +16.5% | ₹15 Cr +58.3% | ₹9 Cr +11.3% | ₹8 Cr -71.2% | ₹29 Cr +135.3% | ₹12 Cr +60.8% | ₹8 Cr -22.3% | ₹10 Cr |
| Total Income | ₹810 Cr +15.3% | ₹702 Cr +20.8% | ₹581 Cr +8.6% | ₹535 Cr -13.4% | ₹618 Cr +21.9% | ₹507 Cr +15.0% | ₹441 Cr +6.8% | ₹413 Cr |
| COGS | ₹212 Cr +11.1% | ₹191 Cr +14.6% | ₹167 Cr +2.1% | ₹163 Cr -3.8% | ₹170 Cr +3.5% | ₹164 Cr +40.0% | ₹117 Cr +5.9% | ₹111 Cr |
| ₹608 Cr +9.5% | ₹555 Cr +14.3% | ₹486 Cr +8.5% | ₹448 Cr +14.7% | ₹390 Cr +10.1% | ₹355 Cr +20.4% | ₹294 Cr +6.9% | ₹275 Cr | |
| Profit Before Tax | ₹195 Cr +33.1% | ₹147 Cr +53.7% | ₹96 Cr +9.4% | ₹87 Cr -61.6% | ₹228 Cr +49.4% | ₹153 Cr +9.0% | ₹140 Cr +1.8% | ₹137 Cr |
| Exceptional Items | (₹6 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹7 Cr) | ₹0.00 Cr |
| ₹60 Cr +9.6% | ₹55 Cr +106.5% | ₹26 Cr +9.3% | ₹24 Cr -53.0% | ₹52 Cr +31.2% | ₹39 Cr -24.4% | ₹52 Cr -1.7% | ₹53 Cr | |
| Net Profit | ₹136 Cr +49.6% | ₹91 Cr +30.6% | ₹69 Cr +8.0% | ₹64 Cr -63.5% | ₹176 Cr +55.7% | ₹113 Cr +28.0% | ₹88 Cr +3.8% | ₹85 Cr |
| Profit (Owners) | ₹138 Cr +50.4% | ₹92 Cr +29.3% | ₹71 Cr +9.7% | ₹64 Cr -63.4% | ₹176 Cr +55.7% | ₹113 Cr +28.0% | ₹88 Cr +3.8% | ₹85 Cr |
| Minority Interest | (₹2 Cr) -151.8% | (₹0.76 Cr) +40.2% | (₹1 Cr) -876.9% | (₹0.13 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | (₹0.51 Cr) +33.8% | (₹0.77 Cr) ↓ Decline | ₹0.29 Cr -81.0% | ₹2 Cr ↑ Recovery | (₹0.08 Cr) +94.2% | (₹1 Cr) ↓ Decline | ₹0.12 Cr +9.1% | ₹0.11 Cr |
| EPS | ₹8.65 | ₹5.76 | ₹4.45 | ₹4.06 | ₹11.10 | ₹7.13 | ₹5.58 | ₹5.38 |
| Diluted Shares | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr |
| Profit Or Loss Of Associates | ₹0.18 Cr ↑ Recovery | (₹1 Cr) ↓ Decline | ₹0.39 Cr -66.9% | ₹1 Cr ↑ Recovery | (₹0.18 Cr) -157.1% | (₹0.07 Cr) ↓ Decline | ₹0.51 Cr -22.7% | ₹0.66 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Docon Technologies Private Ltd has submitted to the Exchange a copy of disclosure under Regulations, 31(1) and 31(2) of SEBI ( SAST) Regulations, 2011.
Please find attached herewith copies of Newspaper Publications published on June 05, 2026, in Business Standard (English) and Navshakti (Marathi)
Please find enclosed herewith copies of Newspaper advertisement published on May 25, 2026 in Business Standard (English) and Pratahkal (Marathi).
Docon Technologies Private Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeov...
Thyrocare Technologies Limited has informed the Exchange about Transcript
Thyrocare Technologies Limited has informed the Exchange about Link of Recording
Thyrocare Technologies Limited has informed the Exchange about Copy of Newspaper Publication of Audited financial results for the quarter and year ended March 31, 2026
Thyrocare Technologies Limited has informed the Exchange about Schedule of meet
Thyrocare Technologies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Thyrocare Technologies Limited has informed the Exchange for the allotment of 3,624 shares pursuant to the exercise of stock options under the Thyrocare Employee Stock Option Scheme.
Thyrocare Technologies Limited has informed the Exchange about Transcript of Earnings Call held on January 28, 2026
Please find attached the Copy of Newspaper Publication on Unaudited Financial results for the quarter and nine months ended on December 31, 2025
Thyrocare Technologies Limited has informed the Exchange about Link of Audio Recording for Investor Call held on January 28, 2026
Thyrocare Technologies Limited has informed the Exchange about Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives.
Thyrocare Technologies Limited has informed the Exchange about Investor Presentation